B. Riley Securities Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $70

Benzinga Newsdesk www.benzinga.com Positive 66.6%

Neg 0% Neu 0% Pos 66.6%

B. Riley Securities analyst Madison El-Saadi reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $70.